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Abstract In February 2011, a group of pathologists from
different departments in Europe met in Zurich, Switzerland,
to discuss opportunities and challenges for pathology in the
era of personalized medicine. The major topics of the meeting
were assessment of the role of pathology in personalized
medicine, its future profile among other biomedical disciplines
with an interest in personalized medicine as well as the evolu-
tion of companion diagnostics. The relevance of novel tech-
nologies for genome analysis in clinical practice was
discussed. The participants recognize that there should bemore
initiatives taken by the pathology community in companion
diagnostics and in the emerging field of next-generation
sequencing and whole genome analysis. The common view
of the participants was that the pathology community has to be
mobilized for stronger engagement in the future of personal-
ized medicine. Pathologists should be aware of the challenges
and the analytical opportunities of the new technologies.
Challenges of clinical trial design as well as insurance and
reimbursement questions were addressed. The pathology
community has the responsibility to lead medical colleagues
into embracing this new area of genomic medicine. Without
this effort, the discipline of pathology risks losing its key
position in molecular tissue diagnostics.
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Background
In the past, pathologists have defined cancer subtypes based
on anatomic origin, clinical behavior, and microscopic mor-
phology. Therapy was based on morphological classification
and extent of spread as translated in stage, as well as protein-
based tests such as immunohistochemistry. Although immu-
nohistochemistry is still the most frequently used approach for
cancer subtyping beyond morphology, the past 10 years have
brought a revolution in the understanding of the molecular
pathology of cancer [1]. We are increasingly aware of its
enormous complexity, mainly due to the emerging technolo-
gies to characterize cancer and to derive its molecular charac-
teristics, which are increasingly relevant in the practice of
oncology. Molecular technologies, such as the identification
of characteristic translocations in leukemias and lymphomas
and categorization of tumor types based on expression
profiling, had changed our understanding of certain cancers
[2, 3]. In solid tumors, the identification of erbB2/HER2
amplification in breast and gastroesophageal cancer led to
the development of anti-HER2 therapeutics (trastuzumab, a
monoclonal antibody; lapatinib, a small molecule tyrosine
kinase inhibitor) that inhibit this protein specifically [4, 5].
Additional examples include c-kit and PDGFRalpha muta-
tions in gastrointestinal stromal tumors [6], tyrosine kinase
mutations of the EGFR gene in lung cancer [7, 8], mutations
in the BRAF gene in melanoma [9], or the EML-ALK gene
rearrangement in lung cancer [10]; all of which have the
potential to render tumors extraordinarily sensitive to specific
inhibitors. Certain biomarkers can also indicate when patients
will not respond to a specific therapy, e.g., K-RAS mutations
which render colorectal cancers unresponsive to anti-epidermal
growth factor receptor (anti-EGFR) therapy with cetuximab or
panitumumab [11, 12]. In recent years, pathologists have con-
tributed profound knowledge to the understanding of these
molecular alterations in specific tumor types [13]. In many of
these examples, routine clinical practice has changed dramati-
cally. However, the majority of patients have tumors that do not
carry these particular genetic changes which therefore do not
respond to such treatment. The percentage of patients respond-
ing to these new drugs is often below 30%. Therefore, future
tasks include profiling these cancers further and to identify
additional molecular aberrations that will lead to better thera-
pies. This should be the focus of intensive research projects
in pathology.
The goal of personalized cancer medicine is to under-
stand the specific characteristics underlying a particular
individual’s disease and then match therapy to the molecular
characteristics of this case. “The right drug, the right dose,
for the right patient, at the right time” is the goal of person-
alized medicine [1]. The personalized approach has two
major problems: complex biology and complex economics
[14, 15]. The European Medicines Agency has already
approved around 15 drugs for cancer therapy that have been
designed to hit a particular molecular target. The pathways
involved are often multiple with complex interactions
between them which are mostly not well understood
[16, 17]. Alterations in various genes, other than the
predicted therapeutic target, can also significantly affect
the response of a patient to a targeted therapy. As an
example, inhibition of the mTOR pathway increases
mitogen-activated protein kinase activity [18]. Therefore,
the complex network of molecular alterations, signaling
pathways, the cellular context, and the response to a
particular therapeutic regimen represents a challenge for
future approaches in personalized medicine.
The economic dimension is due to the fact that most
targeted drugs are extremely expensive. As a result,
healthcare systems and insurance companies are con-
fronted with huge problems caused by rising health care
expenditures. Targeted drugs need to be accompanied by
predictive molecular diagnostic tests to identify suitable
patients, yet many healthcare systems have no mecha-
nism to pay for these tests. These companion “one-gene
tests” are the domain of molecular pathology. Molecular
pathologists have the expertise and the knowledge about
many gene mutations identified by molecular tests; they
have developed quality standards for testing, and they
have developed fellowship training programs in Europe.
The movement towards personalized genomic medicine
is currently associated with the development of novel high
throughput genomic technologies. These tests reach beyond
traditional personalized medicine, enabling the adoption of
personalized genomic medicine. Pathologists should be at
the forefront of embracing such new technologies [19]. An
understanding of modern technologies that profile DNA,
RNA, proteins, and metabolites will be essential for pathol-
ogists to make personalized medicine a reality [19].
Next-generation genomic sequencing—threat
or opportunity?
The human genome sequence was completed more than
10 years ago. Improvements in sequencing technologies
led to the “less than 1,000-dollar genome”, which is now a
reality. At the moment, these new technologies are widely
used in research, but they have the potential to revolutionize
medical practice. Next-generation sequencing technology
may lead to fundamental changes in medical care, where
pathologists could provide the necessary knowledge of
interpreting genomic information in the context of the dis-
ease. However, pathologists have no “birthright” to this
technology [19]. Therefore, next-generation sequencing
(NGS) may challenge their traditional role. Other medical
disciplines and private companies have now their own
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interest in these technologies, even as clinical diagnostic
tests [20]. Such drivers are further pushing pathologists to
demonstrate their expertise in this rapidly evolving area of
personalized medicine. One area where a desperate need
exists is in the organization and coordination of programs
for training in genomic medicine during the pathology res-
idency period. Pathologists should seize the opportunity to
take the lead in the translation of these new technologies and
to demonstrate their value as routine diagnostic tests.
Pathologists also have to prove that genome-based test-
ing is cost-effective, sufficiently rapid, and can optimize
evidence-based precision diagnostics [21, 22]. The patholo-
gy community cannot claim ownership of these most recent
technological innovations in genome sequencing, but should
demonstrate competence in this field. Clinical genetic testing
is also performed by various other specialties, e.g., clinical
pathology, clinical genetics, oncology, clinical chemistry,
microbiology, and pharmacology. With NGS, private,
non-hospital-based companies have begun to offer genetic
testing that might bypass pathology. Examples include
OncotypeDX with their breast cancer assay determining
the expression of the 21-gene panel [23] or new start-up
companies like Foundation Medicine, offering NGS
approaches to cancer genome analyses for personalized
medicine. When NGS and whole genome analysis
(WGA) can be performed at costs that significantly undercut
current charges for single-gene testings, many other institu-
tions outside pathology will offer such clinical tests. It may be
that current “one-gene tests” are replaced by NGS testing that
will be more powerful and more cost-effective. It is imperative
that pathologists take the lead, demonstrating which tests are
most powerful and most cost-effective [21, 22, 24]. Only
when well-designed clinical studies convincingly demonstrate
the predictive value of NGS- or WGA-based tests, will the
implementation of such molecular tumor profiling become
accepted and integrated in diagnosis and treatment of cancer.
Personalized diagnostic technologies will aid in the stratifica-
tion of patients with specific molecular alterations for a clin-
ical trial. It has been shown in the past that pathologists can
significantly contribute to clinical trials, e.g., EORTC trials
with colorectal carcinoma patients [25]. These well-designed
trials allowed identifying the relevance of k-RASmutations in
colorectal cancer. In the future, clinical trial design will be
based on a genotype that can be targeted, rather than the
morphological classification. Selection of patients on the basis
of the mutations their cancer carries will be challenging, but
might be the way to go for types of cancer with specific
mutations at lower frequencies. NSCLC patients, for instance,
can harbor activating mutations in EGFR, but also k-RAS,
BRAF, or translocations involving ALK. Such alterations may
be present in less than 2% of patients with prostate, gastric
cancer, and melanoma, but these may be sensitive to RAF or
MEK inhibitors [26]. The understanding of specific molecular
pathways can also help to interpret clinical trial data and
enhance our understanding of the biology of response or
resistance. Well-designed clinical trials, in combination with
novel genomic technologies, will require the involvement of
pathologists’ expertise, which as a consequence must be
involved very early in the design of clinical trials [27].
Above all, when genomic tests of tumors are considered,
it is essential that the test be performed on nucleic acid
extracts from tumor cells. Certainly for solid tumors, only
pathologists can make this determination; genomic analysis
in the absence of pathologic assessment risks the generation
of meaningless results.
Pathology today—strengths and weaknesses
Personalized genomic medicine is an issue for the entire
field of medicine. The medical community now has the task
of integrating this new domain into medical practice [19].
Pathology should take leadership in personalized genomic
medicine by partnering with other medical disciplines. Diverse
disciplines such as genetics, clinical chemistry, microbiology,
immunology, and bioinformatics are engaged in molecular
diagnostics. These specialists should work closely together
with pathologists. At the moment, pathologists are important
members of all tumor boards, where individualized treatment
decisions are made. We rely on our clinical colleagues to send
us specimens from patients who have sought medical attention
for a specific problem; the case is assessed, diagnosed, and
interpreted and a report is issued. Pathologists are able to
develop a “diagnostic algorithm” with conventional histopa-
thology in combination with immunohistochemistry [28]. This
basic evaluation can be supplemented by disease-specific
analyses such as other “one-gene tests”, and potentially
WGA or NGS. Therefore, pathologists are in a pivotal
position to include and integrate genomic results with
tissue-based morphological assessments to generate a complete
report for the treating oncologist and the patient (Fig. 1).
In Europe, pathologists have different strategies to dem-
onstrate competence and expertise in molecular testing. In
Germany, a quality assurance initiative has been organized.
Interlaboratory tests as part of a quality assurance initiative
in pathology (QuIP) are run under the auspices of the
German Society of Pathology. Similarly, in Italy and Spain,
two quality assurance systems for molecular testing of
EGFR and KRAS mutations under the supervision of the
National Associations of Oncology (AIOM) and Pathology
(SIAPEC) and the Spanish Society of Pathology, respectively,
have been validated. The QuIP system sets quality standards
for all molecular pathology testings. Similar systems exist in
the UK for a number of tissue-based molecular tests, orga-
nized by UK-NEQAS, while EMQN and the European
Society of Pathology also organize molecular testing
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quality assurance programs in various European countries.
These systems demonstrate the expertise of pathology to
perform such tests and to provide the respective quality
assurance programs. National and international recommen-
dations for mutational analysis of EGFR in lung cancer
have been also published [29–32].
Given the high cost of targeted therapies and the require-
ment that these expensive drugs cannot be prescribed with-
out testing, France has found its own solution: In 2005, the
country confirmed payment for treatment of every citizen
shown to be likely to benefit from targeted drugs. Its
National Cancer Institute set up 28 platforms for molecular
genetics at those university hospitals and cancer centers with
expertise in both molecular and pathological analyses. Biop-
sy samples of cancer tissues are sent from all over France, to
these platforms for a battery of around 20 genetic tests. If in
the tissues a molecular signature is identified in any signaling
pathway targeted by one of the drugs, the patient gets treated
with it. The Czech Republic has a similar system. The
French platforms have tested samples from around
50,000 people with lung cancer for alterations in the
EGF pathway [14]. Advantages of the centralized system
include reduced cost due to large volumes of tests, easier
quality control, and free of charge testing for patients.
On the other hand, tests are frequently performed outside
the primary hospital and tissues have to be sent to an
external platform. This can result in a delay of receiving
the test results. Given these differences, a European
commission’s health directorate should help by encouraging
European countries to harmonize their health technology
assessment by giving recommendations.
Personalized medicine has ethical, legal, and social
implications. Privacy issues are a concern for many patients,
which must give their consent for treatment. The public has
to be educated with regard to the impact of genomic testing.
This is a relevant issue for the EU health directory. Further-
more, the requirements for informed consent documents
should be harmonized in the European Union. There is a
need to protect patients’ data, e.g., against discrimination
(issues related to health insurance and employment).
Patients should not have to fear discrimination. Testing for
BRCA1 and BRCA2 genes (implicated in familial breast
and ovarian cancer syndromes) were early examples for the
contribution of germline features to disease prognosis.
Public education on the potential benefits of personalized
cancer medicine and individualized treatments are impor-
tant for its widespread acceptance. When novel next-
generation sequencing technologies enter into clinical
medicine and become standard of care, public education
programs on the ethical, legal, and social implications are
needed for patient protection [33].
Conclusions
The meeting participants agreed that there is a need to develop
a European strategy to ensure that pathologists are involved in
the performance, interpretation, and regulation of omics-based
clinical testing, while recognizing the importance of clinical
trial-based evidence for performing any particular test. Testing
for testing’s sake serves no useful purpose. Pathologists have
Fig. 1 Integration of conven-
tional histopathology, immuno-
histochemistry, and disease-
specific genetic results in lung
cancer
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to develop programs of training and education in genomic
medicine, especially in the evolving technologies of NGS and
WGA. The European Society of Pathology should assess the
current landscape of molecular testing and the reimbursement
situation. It should identify barriers and recommend specific
actions required to develop a European plan for integration of
genomic testing and its interpretation into pathology. It should
be shown that if pathologists take the lead in this arena,
substantial benefits will be realized, not only for the patient,
but also for society at large. The new technologies are very
complex. Therefore, the European Society of Pathology
should assume leadership when it comes to regulatory chal-
lenges for such technologies when performed in pathology
laboratories. This includes evaluation of the performance
claims of the tests based upon scientific evidence. Tests to
be performed in a diagnostic and therapeutic context should
be certified after technical validation, notably but not only
when it comes to many “in-house-developed tests”. The
European Society of Pathology should publish standards on
assay validation and performance. Consensus recommenda-
tions to clinicians and oncologists would also be helpful for
personalized medicine, especially in a time with competing
test on a commercial market. The European Society of Pathol-
ogy, through its working group in molecular pathology,
should distribute information on clinical trials and issue guide-
lines on clinical policy in oncology based on the “levels of
evidence” approach. Guidelines of the European Society of
Pathology would be helpful for different countries to select
specific technologies into routine tissue testing.
The future of pathology lies in personalized medicine
[19, 34, 35]. Pathologists have the obligation to take a lead
in changing both their role, and prevailing attitudes towards
that role, away from “just looking into the microscope”,
towards “integrating the results of both histology and
molecular diagnostics” for the benefit of patients. Pathologists
must learn to manage the clinical decision-making process by
coordinating histological diagnosis and molecular measure-
ments. Pathologists must get prepared to understand their new
role, expand their profile, and take new responsibilities.
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